Maxim Group resumed coverage of Adamis Pharmaceuticals with a rating of Hold

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, issued the following letter to stockholders from Chief Executive Officer David J. Marguglio. ADAMIS HAS NEW LEADERSHIP COMMITTED TO ENHANCING SHAREHOLDER VALUE YOUR SUPPORT AT THE ANNUAL MEETING IS CRITICAL TO OUR FUTURE SUCCESS July 21, 2022 Dear Fellow Stockholder: Thank you for your ongoing investment in Adamis Pharmaceuticals Corporation ("we," "our," "Adamis" or the "Company"). Like

SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Vickie Reed as a new director and member of the company's board of directors. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Ms. Reed to the Board and look forward to working with her to pursue long-term stockholder value. Her substantial expertise as a healthcare executive in financial leadership roles at several public companies, and extensive background in finance and accounting, combined with her experience as a director of another public life science company, should allow her to have an immediate positive impact as Adamis exec

David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory diseases, today announced a leadership transition plan to support its efforts to unlock long-term growth and value creation opportunities: David J. Marguglio, Co-Founder and Chief Business Officer, has been appointed President and Chief Executive Officer, effective immediately. Dennis J. Carlo, Ph.D., has re

SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. "Dick has provided almost eight years of strategic leadership and committed service to Adamis and has provided valuable insight and counsel to the board as well as our staff. He has been an exemplary leader through the challenges the company has faced and has been fair and unwavering in his support for Adamis," said Adamis' CEO and President, Dr. Dennis J. Carlo. "We admire Dick for his work ethic and wish him all the best in his retirement." About Adamis Pharmaceuticals Adamis Pharmaceuticals Corporation i

SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the appointment of Meera J. Desai, Ph.D., as a new director and member of the company's board of directors. Dr. Desai replaces Roshawn Blunt, who retired from the Board effective October 1, 2021. Richard Williams, Chairman of the Board, commented: "We are pleased to welcome Dr. Desai to the Board and look forward to working with her to pursue long-term value creation. Her substantial expertise in international pharmaceutical licensing, combined with her background in drug development and commercialization will help us refine corporate strategy to maximize our product pipeline. I

SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that David C. Benedicto, who has been serving as the Company's Chief Accounting Officer, will succeed Robert O. Hopkins as Chief Financial Officer, effective immediately. Mr. Hopkins is departing to pursue new opportunities after serving the Company for the past 14 years. Management has established a comprehensive transition plan to maintain full continuity across all finance functions as Mr. Hopkins departs. Dr. Dennis J. Carlo, Chief Executive Officer of Adamis, commented: "David has been an important member of our finance team since he joined Adamis nearly seven years ago. In a

Based on Results Provided by the Inspector of Election, Stockholders Re-Elected All Five Members of the Company's Board of Directors Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) ("Adamis" or the "Company") today announced that based on the Inspector of Election's certified results from the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting"), each of the Company's nominees – Howard C. Birndorf, Roshawn A. Blunt, Dennis J. Carlo, Ph.D., David J. Marguglio and Richard C. Williams – have been re-elected to the Board of Directors (the "Board"). According to the Inspector of Election's report, stockholders approved all other proposals considered at the Annual Meeting, includ